Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Overview

Explore Rhythm Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

RYTM●NASDAQ
HealthcareBiotechnology
$112.16
$1.79(1.57%)
U.S. Market opens in 3h 58m

Rhythm Pharmaceuticals, Inc. (RYTM)

Meyka AI Score

Z

Key Financials

Market Cap7.8B
P/E Ratio-39.37
EPS (TTM)$-3.11
ROE-0.84%
Fundamental Analysis

AI Price Forecasts

1 Month$122.92
3 Months$96.68
1 Year Target$122.04

RYTM Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Rhythm Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RYTM on the NASDAQ shows an RSI of 65.44, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $122.04 for the NASDAQ listing.

Key metrics behind Rhythm Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -39.37 and a market capitalization of 7.8B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RYTM on the NASDAQ.

Price Performance (NASDAQ: RYTM)

1-Day Change
-1.57%
5-Day Change
4.72%
1-Month Change
23.55%
3-Month Change
-0.61%
6-Month Change
28.34%
Year-to-Date (YTD) Change
4.78%
1-Year Change
12.32%
3-Year Change
291.62%
5-Year Change
730.20%
All-Time (Max) Change
273.87%

Contact Information

https://www.rhythmtx.com
857 264 4280
222 Berkeley Street, Boston, MA, 02116

Company Facts

4,140 Employees
IPO DateOct 9, 2017
CountryUS
Actively Trading

Frequently Asked Questions